FDA issues warning for two hepatitis C drugs

Two Hepatitis C drugs - Viekira Pak and Technivie - have been linked to serious liver damage.
Two Hepatitis C drugs - Viekira Pak and Technivie - have been linked to serious liver damage.

HealthDay News — Viekira Pak and Technivie may be linked to serious liver damage in patients with advanced liver disease, according to a warning issued by the FDA.

Of 26 cases reported worldwide where use of the medications has been the possible or probable cause of illness, 10 patients either died or required organ transplant after liver failure, and 16 patients had some form of liver dysfunction. In most cases, liver damage occurred within one to four weeks of patients starting treatment, the FDA said. The cases occurred after the two drugs were approved by the FDA—Viekira Pak in December of 2014 and Technivie in July of 2015. The agency believes that there may be other cases that have gone unreported.

Based on the reports, the FDA is now warning that "Viekira Pak and Technivie may cause serious liver injury, including life-threatening liver failure, mainly in patients with underlying advanced liver disease." And, "as a result," the agency added, "we are requiring the manufacturer to add new information about this safety risk to the drug labels."

The FDA says that anyone taking Viekira Pak or Technivie who begins experiencing "fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools" should contact his or her doctor immediately, as these symptoms might indicate liver injury. According to the FDA, before taking Viekira Pak or Technivie, patients should tell their doctors if they have liver problems other than hepatitis C infection, have HIV infection, or are taking birth control pills that contain ethinyl estradiol.

Reference

  1. Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury. Silver Spring, MD: U.S. Food and Drug Administration; 2015.
Loading links....
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters